Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.60 |
| ▸ | TTK | P33981 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207598 | 0.91 | ALK (0.72) | LRRK2ALKMAP3K9MKNK2 | |
| SCHEMBL12917644 | 0.90 | LRRK2 (0.66) | LRRK2JAK2MAP3K9MKNK2TTK | |
| SCHEMBL7449637 | 0.83 | LRRK2 (0.84) | LRRK2JAK2MAP3K9MKNK2TTK | |
| SCHEMBL12917662 | 0.83 | LRRK2 (0.64) | LRRK2JAK2MAP3K9MKNK2TTK | |
| SCHEMBL18018791 | 0.83 | LRRK2 (0.72) | LRRK2ALKMAP3K9MKNK2TTK | |
| SCHEMBL12780545 | 0.82 | LRRK2 (0.66) | LRRK2JAK2MAP3K9MKNK2TTK | |
| SCHEMBL12917681 | 0.82 | LRRK2 (0.55) | LRRK2ALKJAK2MKNK2TTK | |
| SCHEMBL12780185 | 0.81 | LRRK2 (0.57) | LRRK2JAK2MAP3K9MKNK2TTK | |
| SCHEMBL11916501 | 0.81 | ALK (0.64) | LRRK2ALKJAK2MAP3K9MKNK2 | |
| SCHEMBL10208081 | 0.81 | LRRK2 (0.71) | LRRK2ALKMAP3K9MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | LRRK2 3157/4885ALK 3200/4885JAK2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.